Belatacept in kidney transplant patients with systemic lupus erythematosus.
Irene Carrión-BarberàMelissa FajardoGeorge DaniasDemetra TsapepasYevgeniya GartshteynHilda FernandezAnca AskanasePublished in: Lupus science & medicine (2019)
Belatacept in LN kidney transplant recipients may decrease extrarenal manifestations, attenuate CNI toxicity and stabilise allograft function, providing a better alternative to CNI regimens. Furthermore, these data suggest that belatacept, although initiated for reasons not related to SLE, might have a beneficial effect in SLE.